# A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07777211/  
OnCo record `nct07777211` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.

## Summary

A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07777211 by Beijing Gene Key Life Technology Co., Ltd, with 52 participants enrolled, started 2025-08-14 and due to reach its primary completion in 2027-03-31. Interventions recorded: GKL-006 injection and Nab-paclitaxel and Gemcitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07777211
- Phase: 1/2
- Setting: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
- Sponsor: Beijing Gene Key Life Technology Co., Ltd
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT07777211: https://clinicaltrials.gov/study/NCT07777211

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [Beijing Gene Key Life Technology](https://onco.cc/companies/beijing-gene-key-life-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct07777211.json